Assertio Announces Publication of Rolvedon® Same-Day Dosing Clinical Trial

Core Viewpoint - Assertio Holdings, Inc. announced the publication of clinical trial results for Rolvedon® (eflapegrastim-xnst) in The Oncologist, highlighting its effectiveness in early-stage breast cancer patients when administered on the same day as TC chemotherapy [1]. Group 1 - The clinical trial focused on patients with early-stage breast cancer (ESBC) [1]. - Rolvedon demonstrated efficacy when given on the same day as TC chemotherapy, which includes Taxotere (docetaxel) and cyclophosphamide [1].